Global Benign Prostatic Hyperplasia Drugs Market, By Drug Type (Alpha-Blockers, 5-Alpha Reductase Inhibitors, Alpha-Adrenergic Blockers, Phosphodiesterase Type-5 Inhibitors, Beta-Blockers, Others), Treatment Type (Medication, Surgery, Other), Dosage (Tablet, Capsule, Others), Route of Administration (Oral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Benign Prostatic Hyperplasia Drugs Market
Global benign prostatic hyperplasia drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6% in the above mentioned forecast period.
Benign prostatic hyperplasia (BPH) is a condition in men which causes enlargement of prostate gland. An enlarged prostate gland can results in the uncomfortable urinary symptoms such as nocturia or blockage of the urine flow out of the bladder. This condition can also cause bladder, kidney or urinary tract problems. Benign prostatic hyperplasia is also known as benign prostatic hypertrophy or benign prostatic obstruction.
For the treatment of benign prostatic hyperplasia, combination drugs are used as they are more effective and help in the prevention of disease progression. Combination drugs have fewer side effects, reduce the development of drug resistance and also have low treatment failure rate.
Rise in the prevalence of benign prostatic hyperplasia, the increasing geriatric population mainly geriatric male segment, growing preferences for minimally invasive surgeries, growing government initiatives and rising awareness are the factors that will expand the global benign prostatic hyperplasia drugs market.
Rising R&D activities, emerging market and growing demand for more effective treatment which results in strong product pipeline will provide beneficial opportunities for the global benign prostatic hyperplasia drugs market in the forecast period of 2021-2028.
Side effects of alpha-blockers include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Finasteride and Dutasteride convert testosterone to dihydrotestosterone. All these side effects of medication, lack of awareness and high cost of treatment will hamper the market growth and will further challenge the global benign prostatic hyperplasia drugs market in the forecast period mentioned above.
This benign prostatic hyperplasia drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global benign prostatic hyperplasia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Benign Prostatic Hyperplasia Drugs Market Scope and Market Size
The benign prostatic hyperplasia drugs market is segmented on the basis of drug type, treatment type, dosage, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of drug type, the benign prostatic hyperplasia drugs market is segmented into alpha-blockers, 5-alpha reductase inhibitors, alpha-adrenergic blockers, phosphodiesterase type-5 inhibitors, beta-blockers, Others. Alpha-blockers have been further sub-segmented into alfuzosin, doxazosin, tamsulosin, silodosin and other alpha blockers. 5-Aplha reductase inhibitors have been further sub-segmented into finasteride and dutasteride.
On the basis of treatment type, the benign prostatic hyperplasia drugs market is segmented into medication, surgery and other. Surgery has been further sub-segmented into transurethral resection of the prostate (TURP), transurethral microwave thermotherapy (TUMT), transurethral needle ablation of the prostate (TUNA), laser therapy, prostatic stenting, and others.
- On the basis of dosage, the benign prostatic hyperplasia drugs market is segmented into tablet, capsule, and others.
- On the basis of route of administration, the benign prostatic hyperplasia drugs market is segmented into oral and others.
- On the basis of end-users, the benign prostatic hyperplasia drugs market is segmented into clinics, hospital and others.
- The benign prostatic hyperplasia drugs market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy.
Global Benign Prostatic Hyperplasia Drugs Market Country Level Analysis
Global benign prostatic hyperplasia drugs market is analyzed, and market size information is provided by the country, drug type, treatment type, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global benign prostatic hyperplasia drugs market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the benign prostatic hyperplasia drugs market due to the presence of major key players, rising geriatric and obese population, availability of research funding, well-developed healthcare sector, increasing prevalence of disease, and increasing awareness towards health in this region. Global benign prostatic hyperplasia drugs market in the Asia-Pacific and Europe is expected to grow during the forecast period due to the increasing research and development activities, rising investment in the healthcare sector, rising disposable income, high population base and growing government intitatives for spreading awareness about benign prostatic hyperplasia and its treatment.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Global benign prostatic hyperplasia drugs market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Benign Prostatic Hyperplasia Drugs Market Share Analysis
Global benign prostatic hyperplasia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global benign prostatic hyperplasia drugs market.
The major players covered in the global benign prostatic hyperplasia drugs market report are Allergan, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Lilly, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi, Nymox Pharmaceuticals Corporation, Novartis AG, Pfizer Inc., Aeterna Zentaris, IntelGenx Corp., Bayer AG, Merck Sharp & Dohme Corp., Ipsen Pharma, Bausch Health Companies Inc., Quest PharmaTech Inc., Bristol-Myers Squibb Company, Kaken Pharmaceutical Co.,Ltd., GemVax & KAEL and Kissei Pharmaceutical Co., Ltd., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-